{
    "nctId": "NCT00188604",
    "briefTitle": "The Use of Selenium to Treat Secondary Lymphedema - Breast Cancer",
    "officialTitle": "A Randomized Phase II Placebo-controlled Double Blind Study of Using Selenium in the Treatment of Secondary Lymphedema in Breast Cancer Patients",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms, Lymphedema",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 34,
    "primaryOutcomeMeasure": "To assess the effectiveness of orally administered selenium compared to placebo in reducing arm lymphedema in patients treated with surgery (axiallary nodal dissection) and radiotherapy for breast cancer.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* patients with clinically documented lymphedema of upper limb secondary to breast cancer management (surgery - axillary nodal dissection, and radiotherapy)\n* patients who have had other modalities of management can be included, e.g. physical therapy, pharmacological therapy\n* ECOG performance 0-2\n* informed consent\n\nExclusion Criteria:\n\n* active cellulitis/skin infection of the limb\n* venous thrombosis of the upper limbs\n* active malignancy\n* any other medical condition or congenital or traumatic injury involving either limb\n* patients already on selenium medication\n* patients participating in another clinical study related to lymphedema",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}